Modulation of Hemopoiesis in Normal and Tumor-Bearing Mice on in Vivo Administration of FK565

The present investigations were undertaken to study the effect of in vivo administration of FK565 on the process of hemopoiesis in normal and tumor-bearing mice. FK565 administration (10 mg/kg body weight) of normal mice resulted in an enhancement of the bone marrow cell (BMC) colony foming activity (CFA) and proliferation in vitro. The counts of granulocyte- and granulocyte macrophage-colony forming units (CFU-G and CFU-GM) were significantly enhanced in the BMC of FK565-treated group. The total leukocyte count (TLC) was also augmented after FK565 administration. The differential leukocyte count (DLC) revealed an enhancement of the neutrophil count in the FK565-treated mice. A similar pattern of BMC proliferation, CFA, TLC and DLC was observed in P815 tumor-bearing mice. FK565 administration of the tumor-bearing mice, however, did not significantly alter the CFA, TLC and DLC.